EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 42 / No 3 (Mars 2026) Med Sci (Paris), 42 3 (2026) 280-289 References
Issue
Med Sci (Paris)
Volume 42, Number 3, Mars 2026
COVID long : une maladie chronique émergente ?
Page(s) 280 - 289
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2026036
Published online 20 March 2026
  1. Ely EW, Brown LM, Fineberg HV. Long Covid defined. N Engl J Med 2024; 391 : 1746–53. [Google Scholar]
  2. Mouton W, Djebali S, Villard M, et al. Immunological and clinical markers of post-acute sequelae of COVID-19: insights from mild and severe cases 6 months post-infection. Eur J Immunol 2025; 55 : e51948. [Google Scholar]
  3. Sylvester SV, Rusu R, Chan B, et al. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr Med Res Opin 2022; 38 : 1391–9. [Google Scholar]
  4. Yamashita LD, Desai N, Manning AR, et al. Clinical phenotyping of long COVID patients evaluated in a specialized neuro-COVID clinic. Ann Clin Transl Neurol 2025; 12 : 1126–34. [Google Scholar]
  5. Choudhury NA, Mukherjee S, Singer T, et al. Neurologic manifestations of long COVID disproportionately affect young and middle-age adults. Ann Neurol 2025; 97 : 369–83. [Google Scholar]
  6. Bossley CJ, Kavaliunaite E, Harman K, et al. Post-acute COVID-19 outcomes in children requiring hospitalisation. Sci Rep 2022; 12 : 8208. [Google Scholar]
  7. Buonsenso D, Pujol FE, Munblit D, et al. Clinical characteristics, activity levels and mental health problems in children with long coronavirus disease: a survey of 510 children. Future Microbiol 2022; 17 : 577–88. [Google Scholar]
  8. Openshaw JJ, Chen J, Rodriguez R, et al. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection on long-term symptoms in the innovative support for patients with SARS-CoV-2 infections registry (INSPIRE). Clin Infect Dis 2025; 81 : 416–26. [Google Scholar]
  9. Xie YC, Taeyoung; and Al-Aly, Ziyad. Postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras. New Engl J Med 2024; 391 : 515–25. [Google Scholar]
  10. Mazza MG, Palladini M, Poletti S, Benedetti F. Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs 2022; 36 : 681–702. [Google Scholar]
  11. Brandstetter Figueroa E, Frosch AEP, Burrack KS, et al. Viral burden and illness severity during acute SARS-CoV-2 infection predict persistent long COVID symptoms. Open Forum Infect Dis 2025; 12 : ofaf048. [Google Scholar]
  12. Babalola TK, Clouston SAP, Sekendiz Z, et al. SARS-COV-2 re-infection and incidence of post-acute sequelae of COVID-19 (PASC) among essential workers in New York: a retrospective cohort study. Lancet Reg Health Am 2025; 42 : 100984. [Google Scholar]
  13. Chow NKN, Tsang CYW, Chan YH, et al. The effect of pre-COVID and post-COVID vaccination on long COVID: A systematic review and meta-analysis. J infect 2024; 89 : 106358. [Google Scholar]
  14. Wang HI, Doran T, Crooks MG, et al. Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England. J infec 2024; 89 : 106235. [Google Scholar]
  15. Zang C, Hou Y, Schenck EJ, et al. Identification of risk factors of Long COVID and predictive modeling in the RECOVER EHR cohorts. Commun Med 2024; 4 : 130. [Google Scholar]
  16. Lee CY, Liang YC, Hsu WH, et al. Malnutrition and the post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection: a multi-institutional population-based propensity score-matched analysis. Life (Basel) 2024; 14 : 746. [Google Scholar]
  17. Nakayama EE, Shioda T. Detrimental effects of anti-nucleocapsid antibodies in SARS-CoV-2 infection, reinfection, and the post-acute sequelae of COVID-19. Pathogens 2024; 13 : 1109. [Google Scholar]
  18. Wang YC, Tsai CH, Wang YC, et al. SARS-CoV-2 nucleocapsid protein, rather than spike protein, triggers a cytokine storm originating from lung epithelial cells in patients with COVID-19. Infection 2023; 52 : 955–83. [Google Scholar]
  19. Padhye AS, Koralnik IJ, Hanson BA, et al. Blood diagnostic biomarkers for neurologic manifestations of long COVID. Brain Behav Immun Health 2025; 49 : 101110. [Google Scholar]
  20. Zheng L, Zhang L, Zheng Y, et al. Digestive system infection by SARS-CoV-2: Entry mechanism, clinical symptoms and expression of major receptors (Review). Int J Mol Med 2023; 51 : 19. [Google Scholar]
  21. Ishikura T, Nakano T, Kitano T, et al. Serum ferritin level during hospitalization is associated with Brain Fog after COVID-19. Sci Rep 2023; 13 : 13095. [Google Scholar]
  22. Peter RS, Nieters A, Göpel S, et al. Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study. PLoS Med 2025; 22 : e1004511. [Google Scholar]
  23. Lammi V, Nakanishi T, Jones SE, et al. Genome-wide association study of long COVID. Nat Genet 2025; 57 : 1402–17. [Google Scholar]
  24. Petrova B, Syphurs C, Culhane AJ, et al. MTHFR allele and one-carbon metabolic profile predict severity of COVID-19. Proc Natl Acad Sci USA 2025; 122 : e2509118122. [Google Scholar]
  25. Neu F, Nay S, Schuchardt S, et al. Targeted metabolomics identifies accurate CSF metabolite biomarkers for the differentiation between COVID-19 with neurological involvement and CNS infections with neurotropic viral pathogens. J Trans Med 2024; 22 : 620. [Google Scholar]
  26. Visvabharathy L, Hanson BA, Orban ZS, et al. Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein. Front Immunol 2023; 14 : 1155770. [Google Scholar]
  27. Hattori F, Nishiyama J, Hasuo H. Correlation of interferons and autoimmune aspects in long COVID-19 patients. Int Immunol 2025; 37 : 355–63. [Google Scholar]
  28. Visvabharathy L, Dalil N, Leonor L, et al. Mild primary or breakthrough SARS-CoV-2 infection promotes autoantibody production in individuals with and without neuro-PASC. ImmunoHorizons 2024; 8 : 577–85. [Google Scholar]
  29. Glynne PTN; Gant, V.; Gupta, R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med 2022; 70 : 61–7. [Google Scholar]
  30. Hayden MR, Tyagi SC. Impaired folate-mediated one-carbon metabolism in type 2 diabetes, late-onset alzheimer’s disease and long COVID. Medicina (Kaunas) 2021; 58 : 16. [Google Scholar]
  31. Clouston SAP, Vaska P, Babalola T, et al. Glial activation among individuals with neurological post-acute sequelae of coronavirus disease 2019: A positron emission tomography study of brain fog using [18F]-FEPPA. Brain Behav Immun Health 2025; 44 : 100945. [Google Scholar]
  32. Palladini M MM, Bravi B, Bessi M, et al. Sex-specific inflammatory profiles affect neuropsychiatric issues in COVID-19 survivors. Biomolecules 2025;15 : 600. [Google Scholar]
  33. Carreras-Vidal L, Pacheco-Jaime L, Ariza M, et al. Functional brain abnormalities in post COVID-19 condition and their relationship with cognition. Sci Rep 2025; 15 : 22259. [Google Scholar]
  34. Braga J, Lepra M, Kish SJ, et al. Neuroinflammation after COVID-19 with persistent depressive and cognitive symptoms. JAMA Psychiatry 2023; 80 : 787–95. [Google Scholar]
  35. Jacob Y, Morris LS, Verma G, et al. Altered hippocampus and amygdala subregion connectome hierarchy in major depressive disorder. Transl Psychiatry 2022; 12 : 209. [Google Scholar]
  36. Blossom V, Ullal SD, D’Souza MM, et al. Implicating neuroinflammation in hippocampus, prefrontal cortex and amygdala with cognitive deficit: a narrative review. 3 Biotech 2025; 15 : 320. [Google Scholar]
  37. Zhong W, Barde S, Mitsios N, et al. The neuropeptide landscape of human prefrontal cortex. Proc Natl Acad Sci USA 2022; 119 : e2123146119. [Google Scholar]
  38. Rua C, Raman B, Rodgers CT, et al. Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations. Brain 2024; 147 : 4121–30. [Google Scholar]
  39. Bravi B, Paolini M, Colombo F, et al. Long term effect of COVID-19 on brain metabolism and connectivity. Neuroscience 2025; 580 : 1–8. [Google Scholar]
  40. Crunfli F, Carregari VC, Veras FP, et al. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc Natl Acad Sci USA 2022; 119 : e2200960119. [Google Scholar]
  41. Khodanovich M, Svetlik M, Kamaeva D, et al. Demyelination in Patients with POST-COVID Depression. J Clin Med 2024; 13 : 4692. [Google Scholar]
  42. Du Y, Zhang A, Li Z, et al. Role of astrocytic mu-opioid receptors of the ventrolateral periaqueductal gray in modulating anxiety-like responses. Behav Brain Funct 2025; 21 : 24. [Google Scholar]
  43. Barde S, Aguila J, Zhong W, et al. Substance P, NPY, CCK and their receptors in five brain regions in major depressive disorder with transcriptomic analysis of locus coeruleus neurons. Eur Neuropsychopharmacol 2024; 78 : 54–63. [Google Scholar]
  44. Cole RH, Allichon MC, Joffe ME. Opioid Receptors Modulate Inhibition within the Prefrontal Cortex through Dissociable Cellular and Molecular Mechanisms. J Neurosci 2025; 45 : e1963242025. [Google Scholar]
  45. Coleon A, Larrous F, Kergoat L, et al. Hamsters with long COVID present distinct transcriptomic profiles associated with neurodegenerative processes in brainstem. Nat Commun 2025; 16 : 6714. [Google Scholar]
  46. Theoharides TC, Kempuraj D. Role of SARS-CoV-2 spike-protein-induced activation of microglia and mast cells in the pathogenesis of neuro-COVID. Cells 2023; 12 : 688. [Google Scholar]
  47. Hanson BA, Visvabharathy L, Ali ST, et al. Plasma biomarkers of neuropathogenesis in hospitalized patients with COVID-19 and those with postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm 2022; 9 : e1151. [Google Scholar]
  48. Isman A, Nyquist A, Strecker B, et al. Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain Behav Immun Health 2024; 36 : 100733. [Google Scholar]
  49. Proal AD, VanElzakker MB, Aleman S, et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol 2023; 24 : 1616–27. [Google Scholar]
  50. Henri J, Minder L, Mohanasundaram K, et al. Neuropeptides, new ligands of SARS-CoV-2 nucleoprotein, a potential link between replication, inflammation and neurotransmission. Molecules 2022; 27 : 8094. [Google Scholar]
  51. Sherif ZA, Gomez CR, Connors TJ, et al. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). Elife 2023; 12 : e86002. [Google Scholar]
  52. de Melo GD, Lazarini F, Levallois S, et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med 2021; 13 : eabf8396. [CrossRef] [PubMed] [Google Scholar]
  53. Moen JK, Baker CA, Iwasaki A. Neuroimmune pathophysiology of long COVID. Psychiatry Clin Neurosci 2025; 79 : 514–30. [Google Scholar]
  54. Rutkai I, Mayer MG, Hellmers LM, et al. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat Commun 2022; 13 : 1745. [CrossRef] [PubMed] [Google Scholar]
  55. Wong AC, Devason AS, Umana IC, et al. Serotonin reduction in post-acute sequelae of viral infection. Cell 2023; 186 : 4851–67 e20. [Google Scholar]
  56. Slama Schwok A, Henri J. Long neuro-COVID-19: current mechanistic views and therapeutic perspectives. Biomolecules 2024; 14 : 1081. [Google Scholar]
  57. Reid KJ, Ingram LT, Jimenez M, et al. Impact of sleep disruption on cognitive function in patients with postacute sequelae of SARS-CoV-2 infection: initial findings from a Neuro-COVID-19 clinic. Sleep Adv 2024; 5 : zpae002. [Google Scholar]
  58. Yerkenova S, Lokshin V, Kurmanova A, et al. Structural and hormonal changes in reproductive-age women post-COVID-19: a cross-sectional ultrasound and biochemical study. Diagnostics (Basel) 2025; 15 : 1536. [Google Scholar]
  59. Hung LY, Wu CS, Chang CJ, et al. A network medicine approach to investigating ME/CFS pathogenesis in severely ill patients: a pilot study. Front Hum Neurosci 2025; 19 : 1509346. [Google Scholar]
  60. Dong S, Ding F, Wang Y, et al. The relation between FT(3) and long-term fatigue in patients with COVID-19. Front Endocrinol 2024; 15 : 1411262. [Google Scholar]
  61. Giovannoni F, Li Z, Remes-Lenicov F, et al. AHR signaling is induced by infection with coronaviruses. Nat Commun 2021; 12 : 5148. [Google Scholar]
  62. Shi J, Du T, Wang J, et al. Aryl hydrocarbon receptor is a proviral host factor and a candidate pan-SARS-CoV-2 therapeutic target. Sci Adv 2023; 9 : eadf0211. [Google Scholar]
  63. Anderson G, Carbone A., Mazzoccoli G., Aryl hydrocarbon receptor role in co-ordinating SARS-CoV-2 entry and symptomatology: linking cytotoxicity changes in COVID-19 and cancers; modulation by racial discrimination Stress. Biology (Basel) 2020 ; 9 : 249. [Google Scholar]
  64. Safe S, Jin UH, Park H, et al. Aryl hydrocarbon receptor (AHR) ligands as selective AHR modulators (SAhRMs). Int J Mol Sci 2020; 21 : 6654. [Google Scholar]
  65. Leitzke M, Roach DT, Hesse S, et al. Long COVID – a critical disruption of cholinergic neurotransmission? Bioelec Med 2025; 11 : 5. [Google Scholar]
  66. S MB, Calleja DJ, Devine SM, et al. A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID. Nat Commun 2025; 16 : 2900. [Google Scholar]
  67. Terrier O, Dilly S, Pizzorno A, et al. Antiviral properties of the NSAID drug naproxen targeting the nucleoprotein of SARS-CoV-2 coronavirus. Molecules 2021; 26 : 2593. [Google Scholar]
  68. Anastassopoulou C, Davaris N, Ferous S, et al. The molecular basis of olfactory dysfunction in COVID-19 and long COVID. Lifestyle Genom 2024; 17 : 42–56. [Google Scholar]
  69. de Melo GD, Perraud V, Alvarez F, et al. Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants. Nat Commun 2023; 14 : 4485. [Google Scholar]
  70. Blitshteyn S, Funez-dePagnier G, Szombathy A, Hutchinson M. Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and Long COVID: current state and future direction. Front Cellul Infec Microbiol 2025; 15 : 1647203. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.